Biphenyl

Biphenyl

SCHEMBL310004

NC(=O)Cl.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
POLB P06746 1/20 0.50
PARP1 P09874 1/20 0.50
CYP2C19 P33261 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
BCAT2 O15382 1/20 0.50
DHODH Q02127 2/20 0.48
IKBKB O14920 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
WDR5 P61964 1/20 0.48
ABCC4 O15439 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL473288 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRCYP3A4
Biphenyl SCHEMBL5071211 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRL3MBTL1
Biphenyl SCHEMBL4593266 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRCYP3A4
Biphenyl SCHEMBL1952613 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRCYP3A4
Biphenyl SCHEMBL7062651 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRL3MBTL1
Biphenyl SCHEMBL3399859 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRL3MBTL1
Biphenyl SCHEMBL335359 0.88 ALDH1A1 (0.60) ALDH1A1LMNAMAPTTSHRCYP3A4
Biphenyl SCHEMBL5143620 0.85 ALDH1A1 (0.56) ALDH1A1LMNAMAPTTSHRCYP3A4
Biphenyl SCHEMBL27755857 0.84 ALDH1A1 (0.75) ALDH1A1MAPTCYP3A4HSD17B10TDP1
Biphenyl SCHEMBL2901532 0.82 SMN1; SMN2 (0.61) ALDH1A1LMNAMAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503441-B2 Process for preparing diphenylureido-dihalokynurenic acids and tosylate addition salts thereof LOHOCLA RESEARCH CORPORATION 2025-12-23 US claimed
EP-4227297-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF Lohocla Research Corporation (US) 2023-08-16 EP claimed
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF LOHOCLA RESEARCH CORPORATION 2022-05-26 US claimed
CN-103785130-A Fire extinguishing composition containing carboxylic acid derivatives XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY 2014-05-14 CN claimed
US-6962930-B1 Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage LOHOCLA RESEARCH CORPORATION (US) 2005-11-08 US claimed
EP-1011676-B1 QUINOLINE-UREA DERIVATIVES FOR THE TREATMENT OF WITHDRAWAL SYNDROME AND WITHDRAWAL-INDUCED BRAIN DAMAGE LOHOCLA RES CORP (US) 2005-08-31 EP claimed
EP-1011676-A4 COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR AMELIORATION OF WITHDRAWAL SYNDROMES AND WITHDRAWAL-INDUCED BRAIN DAMAGE LOHOCLA RES CORP (US) 2004-08-11 EP claimed
EP-1011676-A1 COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR AMELIORATION OF WITHDRAWAL SYNDROMES AND WITHDRAWAL-INDUCED BRAIN DAMAGE Lohocla Research Corporation (US) 2000-06-28 EP claimed
WO-1998055125-A1 COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR AMELIORATION OF WITHDRAWAL SYNDROMES AND WITHDRAWAL-INDUCED BRAIN DAMAGE LOHOCLA RESEARCH CORPORATION (US) 1998-12-10 WO claimed
US-12503441-B2 Process for preparing diphenylureido-dihalokynurenic acids and tosylate addition salts thereof LOHOCLA RESEARCH CORPORATION 2025-12-23 US disclosed
EP-4227297-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF Lohocla Research Corporation (US) 2023-08-16 EP disclosed
EP-4013416-A1 PROCESS FOR PREPARING 1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLATES AND 4-AMINOQUINOLINE COMPOUNDS THEREFROM Lohocla Research Corporation (US) 2022-06-22 EP disclosed
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF LOHOCLA RESEARCH CORPORATION 2022-05-26 US disclosed
CN-113698312-A Synthetic method of aromatic amide alkene compound 南京先进生物材料与过程装备研究院有限公司 2021-11-26 CN disclosed
EP-0124296-A1 Thermographic system using naphthoylated leuco phenazine dyes MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1984-11-07 EP disclosed
US-4454218-A WITH UNSATURATED COMPOUND AND PHOTOINITIATOR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-12 US disclosed
EP-0103294-A1 N-alkylindolylidene and N-alkylbenzothiazolylidene alkanones as sensitizers for photopolymer compositions E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-03-21 EP disclosed
US-4192677-A ELECTROGRAPHIC CHARGE TRANSFER COMPOUNDS RICOH CO., LTD. (JP) 1980-03-11 US disclosed
US-4141729-A 1,3,4-Oxadiazole derivatives and electrophotographic plates containing same RICOH COMPANY, LTD. (JP) 1979-02-27 US disclosed
US-3932658-A Composition and method for lower blood sugar containing N-[4-(β-<2-methoxy-5-chloro-benzamido>-ethyl)-benzenesulfonyl]-N'-cyclopentyl-urea HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF KMO, KYNU, PAH ALDH1A1 979/4885LMNA 1867/4885MAPT 3949/4885
US-12503441-B2 Process for preparing diphenylureido-dihalokynurenic acids and tosylate addition salts thereof KMO, KYNU, PAH ALDH1A1 979/4885LMNA 1867/4885MAPT 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.